United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

casen recordati s.l. - sodium picosulfate; citric acid monohydrate; magnesium oxide light - oral powder - 10mg ; 12gram ; 3.5gram

Canada - English - Health Canada

recordati rare diseases canada inc - pasireotide (pasireotide diaspartate) - solution - 0.3mg - pasireotide (pasireotide diaspartate) 0.3mg - somatostatin agonists

Canada - English - Health Canada

recordati rare diseases canada inc - pasireotide (pasireotide diaspartate) - solution - 0.6mg - pasireotide (pasireotide diaspartate) 0.6mg - somatostatin agonists

Canada - English - Health Canada

recordati rare diseases canada inc - pasireotide (pasireotide diaspartate) - solution - 0.9mg - pasireotide (pasireotide diaspartate) 0.9mg - somatostatin agonists

Canada - English - Health Canada

recordati rare diseases - carglumic acid - tablet for suspension - 200mg - carglumic acid 200mg - ammonia detoxicants

United States - English - NLM (National Library of Medicine)

recordati rare diseases - betaine (unii: 3scv180c9w) (betaine - unii:3scv180c9w) - betaine 1 g in 1 g - cystadane ® is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood concentrations in pediatric and adult patients. included within the category of homocystinuria are: - cystathionine beta-synthase (cbs) deficiency - 5,10-methylenetetrahydrofolate reductase (mthfr) deficiency - cobalamin cofactor metabolism (cbl) defect none. risk summary available data from a limited number of published case reports and postmarketing experience with cystadane use in pregnancy have not identified any drug associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with betaine. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnanc

United States - English - NLM (National Library of Medicine)

recordati rare diseases, inc. - mechlorethamine hydrochloride (unii: l0mr697hhi) (mechlorethamine - unii:50d9xsg0vr) - mechlorethamine hydrochloride 10 mg in 10 ml

Canada - English - Health Canada

recordati rare diseases canada inc - pasireotide (pasireotide pamoate) - powder for suspension, sustained-release - 20mg - pasireotide (pasireotide pamoate) 20mg - somatostatin agonists

Canada - English - Health Canada

recordati rare diseases canada inc - pasireotide (pasireotide pamoate) - powder for suspension, sustained-release - 60mg - pasireotide (pasireotide pamoate) 60mg - somatostatin agonists

Canada - English - Health Canada

recordati rare diseases canada inc - pasireotide (pasireotide pamoate) - powder for suspension, sustained-release - 40mg - pasireotide (pasireotide pamoate) 40mg - somatostatin agonists